Personalis, Inc. (PSNL): Price and Financial Metrics


Personalis, Inc. (PSNL): $2.38

0.13 (+5.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PSNL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PSNL POWR Grades

  • Value is the dimension where PSNL ranks best; there it ranks ahead of 70.78% of US stocks.
  • PSNL's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • PSNL ranks lowest in Quality; there it ranks in the 3rd percentile.

PSNL Stock Summary

  • With a year-over-year growth in debt of -21.79%, PERSONALIS INC's debt growth rate surpasses just 14.08% of about US stocks.
  • Revenue growth over the past 12 months for PERSONALIS INC comes in at -18.8%, a number that bests just 9.53% of the US stocks we're tracking.
  • In terms of volatility of its share price, PSNL is more volatile than 83.28% of stocks we're observing.
  • Stocks that are quantitatively similar to PSNL, based on their financial statements, market capitalization, and price volatility, are DYAI, ENTX, VLDR, TARS, and EYEN.
  • Visit PSNL's SEC page to see the company's official filings. To visit the company's web site, go to www.personalis.com.

PSNL Valuation Summary

  • In comparison to the median Healthcare stock, PSNL's price/sales ratio is 31.71% lower, now standing at 1.4.
  • PSNL's EV/EBIT ratio has moved up 42 over the prior 44 months.

Below are key valuation metrics over time for PSNL.

Stock Date P/S P/B P/E EV/EBIT
PSNL 2023-01-20 1.4 0.4 -1.0 -0.6
PSNL 2023-01-19 1.5 0.4 -1.0 -0.6
PSNL 2023-01-18 1.6 0.5 -1.1 -0.7
PSNL 2023-01-17 1.8 0.5 -1.2 -0.8
PSNL 2023-01-13 1.9 0.5 -1.3 -0.9
PSNL 2023-01-12 1.8 0.5 -1.2 -0.8

PSNL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PSNL has a Quality Grade of D, ranking ahead of 6.55% of graded US stocks.
  • PSNL's asset turnover comes in at 0.259 -- ranking 67th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows PSNL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.259 0.327 -0.268
2021-03-31 0.311 0.292 -0.325
2020-12-31 0.398 0.256 -0.443
2020-09-30 0.436 0.269 -0.492
2020-06-30 0.482 0.283 -0.583
2020-03-31 0.426 0.315 -0.904

PSNL Price Target

For more insight on analysts targets of PSNL, see our PSNL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.57 Average Broker Recommendation 1.38 (Strong Buy)

PSNL Stock Price Chart Interactive Chart >

Price chart for PSNL

PSNL Price/Volume Stats

Current price $2.38 52-week high $12.96
Prev. close $2.25 52-week low $1.73
Day low $2.19 Volume 192,700
Day high $2.41 Avg. volume 366,678
50-day MA $2.35 Dividend yield N/A
200-day MA $3.52 Market Cap 109.41M

Personalis, Inc. (PSNL) Company Bio


Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.


PSNL Latest News Stream


Event/Time News Detail
Loading, please wait...

PSNL Latest Social Stream


Loading social stream, please wait...

View Full PSNL Social Stream

Latest PSNL News From Around the Web

Below are the latest news stories about PERSONALIS INC that investors may wish to consider to help them evaluate PSNL as an investment opportunity.

Fremont cancer test business Personalis to cut staff by one-third

Cancer test business Personalis Inc. is cutting a third of its staff in a move that's estimated to affect more than 100 workers. It said the layoffs are being done to "reduce operating costs and improve operating efficiency." Personalis didn't specify the number of jobs to be cut but in an annual report last year it said it employed 326 people at the end of 2021.

Yahoo | January 19, 2023

Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce

Personalis Inc (NASDAQ: PSNL) approved a reduction in the company's workforce by up to approximately 30% to reduce operating costs and improve operating efficiency. The reduction in workforce is expected to be completed on March 20, 2023. The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023. The company estimates that the reduction in workforce will save approximately $17 million, net in

Yahoo | January 19, 2023

Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of one-year loss

This week we saw the Personalis, Inc. ( NASDAQ:PSNL ) share price climb by 14%. But that is meagre solace when you...

Yahoo | January 5, 2023

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

FREMONT, Calif., January 04, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022.

Yahoo | January 4, 2023

Can you now get a good deal on Personalis Inc.’s shares?

A share of Personalis Inc. (NASDAQ:PSNL) closed at $2.30 per share on Thursday, down from $2.70 day before. While Personalis Inc. has underperformed by -14.81%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PSNL fell by -83.33%, with highs and lows ranging from $15.28 to $2.18, […]

US Post News | December 16, 2022

Read More 'PSNL' Stories Here

PSNL Price Returns

1-mo 23.96%
3-mo -10.86%
6-mo -34.79%
1-year -77.05%
3-year -79.55%
5-year N/A
YTD 20.20%
2022 -86.12%
2021 -61.02%
2020 235.87%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7938 seconds.